Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance® (empagliflozin) for the treatment of people with chronic heart failure. The trials are targeted to begin within the next 12 months and are planned to enrol people with chronic heart failure both with and without type 2 diabetes (T2D).
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160419005757/en/
Jardiance® was the first diabetes treatment to demonstrate a reduction in the risk of cardiovascular (CV) death in a dedicated CV outcomes trial. This was demonstrated on top of standard of care (including glucose-lowering agents and CV drugs) in people with T2D at high risk of CV events. In addition to reducing CV death by 38 percent, the EMPA-REG OUTCOME® trial also showed that Jardiance® reduced the risk of hospitalisation for heart failure in people with T2D at high risk of CV events by 35 percent. These results led to the planned trials.
“The EMPA-REG OUTCOME trial demonstrated that Jardiance reduces the risk of cardiovascular death in diabetes patients at high cardiovascular risk, and we now look forward to exploring whether Jardiance can also provide heart failure benefits,” said Professor Hans-Juergen Woerle, Global Vice President Medicine, Boehringer Ingelheim.
“One in two people with heart failure die within five years of diagnosis, so there is currently a compelling need for an effective therapy to treat those suffering from this condition,” said Dr Javed Butler, cardiologist, Stony Brook University Hospital.
About heart failure
Heart failure is when the heart cannot pump enough blood around the body. It is a debilitating condition and can be fatal. Heart failure is a prevalent disease; 26 million people around the world and 5.7 million people in the United States have chronic heart failure. Every 35 seconds a new case of heart failure is diagnosed in the United States. There is a high unmet need in the treatment of heart failure as there is significant morbidity and mortality associated with the condition. Heart failure is highly prevalent in patients with diabetes, however, approximately two-thirds of all heart failure patients do not have diabetes.
About Jardiance ®
Jardiance® (empagliflozin) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor approved for use in Europe, the United States and other markets around the world for the treatment of adults with type 2 diabetes.
Jardiance® works by blocking the reabsorption of glucose (blood sugar) by the kidney, leading to urinary glucose excretion and lowering blood glucose levels in people with type 2 diabetes. SGLT2 inhibition targets glucose directly and works independently of β-cell function and the insulin pathway.
Jardiance® is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).
About EMPA-REG OUTCOME ®
EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 patients from 42 countries with type 2 diabetes at high risk for cardiovascular events.
The study assessed the effect of Jardiance® (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.
Over a median of 3.1 years, Jardiance® significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo. Risk of cardiovascular death was reduced by 38 percent, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke. Treatment with Jardiance® also resulted in a 32 percent reduced risk of all-cause mortality and a 35 percent reduced risk of hospitalisation for heart failure.
The overall safety profile of Jardiance® was consistent with that of previous trials. The incidence of diabetic ketoacidosis was at or below 0.1 percent and similar across all treatment groups.
This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.
Please click on the link below for ‘Notes to Editors’ and ‘References’:
Boehringer Ingelheim GmbH
Dr. Ralph Warsinsky
Executive Director Media & PR
Phone: +49 178 290 8561
Director of Communications
Phone: +1 (317) 277 4021
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
WilsonHCG Unveils Fourth Annual Fortune 500 Top 100 Employment Brands Report17.1.2018 14:00 | Pressemelding
WilsonHCG, global leader and premium provider of innovative talent solutions, has revealed its 2018 Fortune 500 Top 100 Employment Brands report – the company’s fourth annual objective research, evaluation and ranking of how well Fortune 500 organizations brand themselves as an “employer of choice”. New to the 2018 report, WilsonHCG also analyzed the top 25 Global Fortune 500 employment brands. Based on six key employment branding categories and tens of thousands of data points, Johnson & Johnson earned the top overall ranking for the second year in a row (third consecutive top-10 performance). Intel earned the No. 2 overall spot, with three companies – IBM, Procter & Gamble and Lockheed Martin – tying for third overall. Rounding out the top 10 are General Motors, JPMorgan Chase, Dow, Cummins, and ADP (each tied for No. 6 overall). “We’re in the midst of the most competitive hiring environment of our time, as today’s talent has full transparency into what they're worth – and what compe
Mavenir Announces Virtualized Media Breakout Controller, Bringing 5G Edge Architectures to Legacy Networks17.1.2018 14:00 | Pressemelding
Mavenir, focused on transforming mobile network economics for Communications Service Providers, today announced its virtualized Media Breakout Controller (vMBC), a single white box routing platform that enables carriers to host virtual Routing, Firewall, and User plane data offload. Today’s networks, whether 3G, 4G or 5G, are under pressure to provide increased bandwidth in support of LTE and its frequency combinations, and reduce latency for network interaction, resulting in a continual need to increase capacity for traffic transported through the core of the network. Multi-Access Edge Computing standardization (MEC) is trying to resolve some of these issues by placing compute functionality at the edge but it is still mostly controlled from the core, based on conventional centralized architectures. The ability to scale network functionality using virtual elements and COTS HW platforms allows network functionality to be deployed at any location. Mavenir’s innovative solution offers the
Greece’s Largest Lender Piraeus Bank to Fully Eliminate ELA in 201817.1.2018 13:42 | Pressemelding
Greece’s Piraeus Bank ends 2017 with NPL stock below EU20b vs EU20.1b target, according to a Bloomberg report. For 2018, the Bank projects a credit growth rate of 1% for the Greek banking sector, with the granting of new loans mainly to corporates and SMEs. This will be the first loan growth since the onset of the crisis. Loan growth is expected to come mainly from corporate and SME lending. In 2017 Piraeus, which holds a dominant position in the SMEs market (80% of the SMEs market having a banking relationship with Piraeus Bank), generated close to €2.8bn new loans, ahead of its budget, targeting to be close to €5bn by 2020. Loans to deposit ratio converging towards 100%, signaling the readiness of the Bank to satisfy stronger loan demand coming. The Bank has reduced its ELA reliance significantly to €5.5bn level at the end of 2017 from €12bn at the beginning of the year, currently below €4.5bn. “We have delivered a significant reduction in euro-system funding. This is strongly in lin
SailPoint Closes out an Award-Winning Year in 201717.1.2018 13:00 | Pressemelding
SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity management, closed out an award-winning year in 2017, receiving industry recognition spanning technology innovation, business performance and company culture. “Last year was a phenomenal one for SailPoint on many fronts. Our goal as a company has always been to focus on delivering innovative solutions to address our customers’ identity needs, so to see that innovation highlighted by industry analysts is great validation for us,” said Mark McClain, CEO and Co-founder of SailPoint. “Likewise, our people are invaluable to us as they truly drive our company’s innovation and exemplify our core values daily, so to have them provide such positive feedback is an incredible recognition for all of us as team.” Key award wins and industry accolades achieved to close out 2017 include: SailPoint was named one of the fastest growing technology companies on Deloitte’s 2017 Technology Fast 500™ for the fifth consecut
YuppTV White Labelled OTT Platform Equips Aastha Group’s TV Channels Foray in Digital World17.1.2018 12:30 | Pressemelding
Global leader for South-Asian content, YuppTV powers Aastha Group’s TV Channels (Aastha, Aastha Bhajan, Vedic & Arihant) voyage into the world of OTT. Aastha, the pioneer spiritual and cultural brand will be utilising YuppTV’s white-labelled video platform to be present across the digital world of web, mobile, and connected TVs. Aastha mobile app was launched today by Param Pujya Swami Ramdev Ji Maharaj and Shraddhey Shree Acharya Bal Krishan Ji. On this occasion, Swami Ji stated that it's the beginning of a new era in the journey of Aastha the leading Indian Channel on spirituality and natural wellness through Yoga and Ayurveda. “Aastha” App would bring people across the world closer to Indian spirituality and meditation. Now, one can watch their favourite programs of previous nine days on “Aastha” Mobile App. anytime anywhere, as per their convenience. Extending the words of Swami Ramdev Ji, Shraddhey Balkrishan Ji said that the “Aastha” Mobile app would play a huge role in connectin
Nasdaq Will Use Rimini Street for Support of Some of Its Internal Corporate Systems17.1.2018 12:00 | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that Nasdaq will use Rimini Street for support of its human resource management system. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180117005048/en/ Nasdaq will use Rimini Street for Support of Some of its Internal Corporate Systems (Photo: Business Wire) As with all Rimini Street clients, Nasdaq has an assigned dedicated Primary Support Engineer (PSE) as its main point of contact for all support cases. Rimini Street PSE’s have an average of 15 years’ experience in their respective applications, and all clients receive industry-leading 24x7x365 service level commitments. “We are pleased to welcome Nasdaq to the fast-growing Rimini Street family of clients,” said Seth A. Ravin, Rimini Street CEO. “We have been disrupting the ent
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom